Peptide Bio IndexEvidence first. Hype last.
⌕

MOTS-C Reported Study Designs and Protocol Details

Written by

in

Reported Protocols
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited9 min readUpdated Sep 4, 2026
Jump to a section
  1. Scope and types of evidence in the reviewed records
  2. Human/clinical measurements and clinical-translation status
  3. Animal in vivo study designs and reported protocol elements
  4. Cellular, molecular, and cell-free protocol details
  5. Reported outcomes tied to the protocols and key mechanistic notes
  6. Reported study-design details from cited sources
  7. Limitations and research gaps
  8. Documentation checklist
  9. Related research supplies
  10. More MOTS-c research
  11. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This evidence deep dive summarizes reported study designs and protocol details for the mitochondrial-derived peptide MOTS-c as described in the provided reviewed sources. The body of evidence in the reviewed records comprises in vitro mechanistic studies, multiple animal models (mice and rats), and limited clinical/biomarker measurements; explicit administration amounts, routes, and many timing details are frequently not reported in the reviewed excerpts.

Scope and types of evidence in the reviewed records

The reviewed records include a mix of review articles and primary research covering in vitro mechanistic work, cell-free binding assays, multiple animal models (mice and rats), tumor models, and limited clinical biomarker analyses. Reviews note the peptide's identification as a 16–amino-acid mitochondrial-derived peptide and discuss translational potential, while primary studies report molecular mechanisms and in vivo outcomes in disease models. [S1] [S2] [S3] [S4] [S5] [S6] [S8] [S7]

Human/clinical measurements and clinical-translation status

A clinical/biomarker signal is reported in the reviewed sources: one study excerpt describes serum MOTS-c increments within 24 hours after cardiopulmonary bypass that were evaluated as predictors of acute respiratory distress syndrome incidence (reported as a clinical biomarker analysis) (S5). Reviews and primary sources note plasma MOTS-c is detectable and may decline with age, but the reviewed literature indicates that no effective method for clinical application of MOTS-c has been developed and that rigorous human safety data are limited (S1, S7). [S5] [S1] [S7]

Animal in vivo study designs and reported protocol elements

Multiple animal in vivo models are described across the primary studies: mice treated with MOTS-c in diet-induced and age-dependent metabolic models (S2); a gestational diabetes mellitus (GDM) mouse model established by short-term high-fat diet plus low-dose streptozotocin with MOTS-c administered daily during pregnancy (frequency and timing reported as 'daily during pregnancy' but amounts and route not specified in the reviewed excerpt) (S4); rat lung ischemia–reperfusion injury models with exogenous MOTS-c administration assessed for lung-protective effects and serum biomarker changes (S5); and mice receiving MOTS-c in studies of skeletal muscle atrophy and glucose uptake (S8). Many administration specifics such as exact amount, administration route, and full dosing schedules are not reported in the reviewed excerpts. [S2] [S4] [S5] [S8]

Cellular, molecular, and cell-free protocol details

Mechanistic and molecular protocols include cellular metabolic-stress experiments demonstrating MOTS-c translocation to the nucleus and regulation of nuclear gene expression in an AMPK-dependent manner (cellular glucose restriction/metabolic-stress paradigms are described) (S6); cell-free binding assays showing direct binding and activation of CK2 by MOTS-c (S8); and in vitro cancer-cell assays reporting that exogenous MOTS-c inhibits proliferation, migration and invasion and interacts with target proteins such as LARS1 (S3). Specific concentrations, exposure times, and other assay parameters are not detailed in the reviewed excerpts. [S6] [S8] [S3]

Reported outcomes tied to the protocols and key mechanistic notes

Reported outcomes linked to the described experimental protocols include prevention of age-related and high-fat-diet-induced insulin resistance and reduction of diet-induced obesity in mice (S2); alleviation of hyperglycemia, improved insulin sensitivity and glucose tolerance, and improved reproductive outcomes in a GDM mouse model with daily MOTS-c during pregnancy (S4); anti-tumor effects against ovarian cancer cells and in vivo tumor growth reduction without reported systemic toxicity in the reviewed excerpt (S3); attenuation of lung ischemia–reperfusion injury and improved endothelial barrier and oxidative-stress markers in rat LIRI models (S5); nuclear translocation and regulation of nuclear gene expression including antioxidant-response-element genes in response to metabolic stress (S6); and prevention of skeletal-muscle atrophy and enhanced muscle glucose uptake with CK2 engagement in mice (S8). [S2] [S4] [S3] [S5] [S6] [S8]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S2] Journal Article (primary research) mice not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source MOTS-c reported to regulate insulin sensitivity and metabolic homeostasis and to prevent age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice; specific dosing parameters not provided in the reviewed excerpt.
[S4] Journal Article (primary research) mouse (gestational diabetes mellitus model) not reported in the reviewed source not reported in the reviewed source daily during pregnancy GDM model established by short-term high-fat diet combined with low-dose streptozotocin; MOTS-c was administered daily during pregnancy per the reviewed excerpt; amounts and administration route not specified in the excerpt.
[S5] Journal Article (primary research) rat (lung ischemia–reperfusion injury models) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Exogenous MOTS-c administration in rat LIRI models attenuated lung injury and recapitulated endogenous protective mechanisms; serum MOTS-c increments within 24 h post-CPB were evaluated as a clinical biomarker in the reviewed excerpt; specific dosing and route details not provided in the excerpt.
[S8] Journal Article (primary research) mice not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Systemic MOTS-c administration in mice was reported to prevent skeletal muscle atrophy and enhance muscle glucose uptake; cell-free assays showed direct binding and activation of CK2 by MOTS-c; specific dosing parameters not provided in the reviewed excerpt.
[S6] Journal Article (primary research) cellular models and metabolic-stress paradigms (in vitro) not reported in the reviewed source not applicable not reported in the reviewed source not reported in the reviewed source MOTS-c translocation to the nucleus and regulation of nuclear gene expression were shown in response to metabolic stress; findings include AMPK-dependent regulation and interaction with ARE-regulating transcription factors. Specific experimental parameters (e.g., concentrations, exposure times) are not detailed in the reviewed excerpt.
[S3] Journal Article (primary research) ovarian cancer cell models and in vivo tumor model (species not specified in excerpt) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Exogenous MOTS-c inhibited proliferation, migration and invasion of ovarian cancer cells and produced anti-tumor effects in vivo without systemic toxicity reported in the reviewed excerpt; specific dosing, route, and species for in vivo experiments are not provided in the excerpt.

Limitations and research gaps

  • Many reviewed excerpts lack explicit administration details (amounts, routes, full dosing schedules and exposure times); several fields are frequently 'not reported in the reviewed source'.
  • Most evidence in the provided records is preclinical (cell and animal studies); human safety and efficacy data are limited or scarce in the reviewed sources.
  • Clinical translation status remains preliminary in the reviewed literature; the reviewed excerpts do not present registered Phase 3 trials or regulatory approvals for MOTS-c.
  • Heterogeneity in models (different species, disease paradigms, and experimental endpoints) and incomplete protocol reporting limit direct cross-study protocol synthesis.

Documentation checklist

  • Confirm species/model details are present in the primary report before extrapolating protocol parameters.
  • Verify whether amounts, routes, frequency, and duration are explicitly reported in each source (many MOTS-c reports omit these details).
  • Distinguish in vitro, ex vivo, and in vivo data when summarizing outcomes for a given study.
  • Record source identifiers and excerpts alongside any protocol elements to preserve traceability.
  • Cold-chain storage temperature log templates for -80°C sample storage
  • Peptide vial labeling templates and batch inventory sheets
  • Laboratory inventory management spreadsheet template for peptide lots
  • Laboratory surface and equipment cleaning checklist (compatible disinfectants and SOPs)

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.

More MOTS-c research

Sources and references

  1. [S1] Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.. Frontiers in endocrinology. 2023. PMID: 36761202. DOI: 10.3389/fendo.2023.1120533
  2. [S2] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.. Cell metabolism. 2015. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009
  3. [S3] Yin Y, Li Y, Ma B, Ren C, Zhao S, Li J. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024. PMID: 39321430. DOI: 10.1002/advs.202405620
  4. [S4] Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.. Pharmacological research. 2022. PMID: 34798268. DOI: 10.1016/j.phrs.2021.105987
  5. [S5] Li X, Zhan F, Qiu G, Lu P, Shen Z, Qi Y. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.. Redox biology. 2025. PMID: 40403491. DOI: 10.1016/j.redox.2025.103681
  6. [S6] Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.. Cell metabolism. 2018. PMID: 29983246. DOI: 10.1016/j.cmet.2018.06.008
  7. [S7] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
  8. [S8] Kumagai H, Kim SJ, Miller B, Zempo H, Tanisawa K, Natsume T. MOTS-c modulates skeletal muscle function by directly binding and activating CK2.. iScience. 2024. PMID: 39559755. DOI: 10.1016/j.isci.2024.111212

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts